Better Medicines for HIV/AIDS
Developing Selective Inhibitors and Probes for Concentrative Nucleoside Transporters
['FUNDING_R21'] · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · NIH-11146560
This work aims to create new and safer versions of current HIV/AIDS medicines by targeting specific transporters in the body.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSALIND FRANKLIN UNIV OF MEDICINE & SCI (nih funded) |
| Locations | 1 site (NORTH CHICAGO, UNITED STATES) |
| Trial ID | NIH-11146560 on ClinicalTrials.gov |
What this research studies
Many current HIV/AIDS medications, while effective, can cause serious side effects like kidney problems or weight gain. This project focuses on tiny structures in our bodies called nucleoside transporters, which move these medicines around. By understanding how these transporters work, we hope to design new medicines that are just as effective but cause fewer unwanted side effects. Our goal is to make HIV/AIDS treatments safer and more comfortable for patients.
Who could benefit from this research
Good fit: This foundational work is for patients living with HIV/AIDS who currently take or may need nucleoside reverse transcriptase inhibitors (NRTIs) and experience or are at risk for drug-related toxicities.
Not a fit: Patients who do not have HIV/AIDS or are not treated with nucleoside-based therapies would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new HIV/AIDS medications that are more tolerable and have fewer severe side effects for patients.
How similar studies have performed: While the concept of optimizing existing therapies is established, this specific approach of developing selective inhibitors for concentrative nucleoside transporters to reduce HIV/AIDS drug toxicity is a novel area of focus.
Where this research is happening
NORTH CHICAGO, UNITED STATES
- ROSALIND FRANKLIN UNIV OF MEDICINE & SCI — NORTH CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BUOLAMWINI, JOHN K — ROSALIND FRANKLIN UNIV OF MEDICINE & SCI
- Study coordinator: BUOLAMWINI, JOHN K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus